Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten; Michel W J M Wouters; Doranne L Hilarius; John B Haanen; Christian U Blank; Maureen J B Aarts; Franchette W P J van den Berkmortel; Jan-Willem B de Groot; Geke A P Hospers; Ellen Kapiteijn; Djura Piersma; Roos S van Rijn; Karijn P M Suijkerbuijk; Willeke A M Blokx; Bert-Jan J Ten Tije; Astrid A M van der Veldt; Art Vreugdenhil; Marye J Boers-Sonderen; Alfonsus J M van den Eertwegh

doi:10.1038/s41416-021-01312-1

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten
, Michel W J M Wouters
, Doranne L Hilarius
, John B Haanen
, Christian U Blank
, Maureen J B Aarts
, Franchette W P J van den Berkmortel
, Jan-Willem B de Groot
, Geke A P Hospers
, Ellen Kapiteijn
, Djura Piersma
, Roos S van Rijn
, Karijn P M Suijkerbuijk
, Willeke A M Blokx
, Bert-Jan J Ten Tije
, Astrid A M van der Veldt
, Art Vreugdenhil
, Marye J Boers-Sonderen
, Alfonsus J M van den Eertwegh

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021

Original language	English
Article number	1746
Number of pages	1
Journal	British Journal of Cancer
Volume	124
Issue number	10
Early online date	15 Mar 2021
DOIs	https://doi.org/10.1038/s41416-021-01312-1
Publication status	Published - 11 May 2021

Access to Document

10.1038/s41416-021-01312-1

Cite this

van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J.-W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokx, W. A. M., Ten Tije, B.-J. J., van der Veldt, A. A. M., Vreugdenhil, A., Boers-Sonderen, M. J., & van den Eertwegh, A. J. M. (2021). Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. British Journal of Cancer, 124(10), Article 1746. https://doi.org/10.1038/s41416-021-01312-1

@article{e1493a500b5c4b88a7fe060afa01ce45,

title = "Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis",

abstract = "Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021",

author = "\{van Breeschoten\}, Jesper and Wouters, \{Michel W J M\} and Hilarius, \{Doranne L\} and Haanen, \{John B\} and Blank, \{Christian U\} and Aarts, \{Maureen J B\} and \{van den Berkmortel\}, \{Franchette W P J\} and \{de Groot\}, \{Jan-Willem B\} and Hospers, \{Geke A P\} and Ellen Kapiteijn and Djura Piersma and \{van Rijn\}, \{Roos S\} and Suijkerbuijk, \{Karijn P M\} and Blokx, \{Willeke A M\} and \{Ten Tije\}, \{Bert-Jan J\} and \{van der Veldt\}, \{Astrid A M\} and Art Vreugdenhil and Boers-Sonderen, \{Marye J\} and \{van den Eertwegh\}, \{Alfonsus J M\}",

year = "2021",

month = may,

day = "11",

doi = "10.1038/s41416-021-01312-1",

language = "English",

volume = "124",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "10",

}

van Breeschoten, J, Wouters, MWJM, Hilarius, DL, Haanen, JB, Blank, CU, Aarts, MJB, van den Berkmortel, FWPJ, de Groot, J-WB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM , Blokx, WAM, Ten Tije, B-JJ, van der Veldt, AAM, Vreugdenhil, A, Boers-Sonderen, MJ & van den Eertwegh, AJM 2021, 'Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis', British Journal of Cancer, vol. 124, no. 10, 1746. https://doi.org/10.1038/s41416-021-01312-1

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. / van Breeschoten, Jesper; Wouters, Michel W J M; Hilarius, Doranne L et al.
In: British Journal of Cancer, Vol. 124, No. 10, 1746, 11.05.2021.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

AU - van Breeschoten, Jesper

AU - Wouters, Michel W J M

AU - Hilarius, Doranne L

AU - Haanen, John B

AU - Blank, Christian U

AU - Aarts, Maureen J B

AU - van den Berkmortel, Franchette W P J

AU - de Groot, Jan-Willem B

AU - Hospers, Geke A P

AU - Kapiteijn, Ellen

AU - Piersma, Djura

AU - van Rijn, Roos S

AU - Suijkerbuijk, Karijn P M

AU - Blokx, Willeke A M

AU - Ten Tije, Bert-Jan J

AU - van der Veldt, Astrid A M

AU - Vreugdenhil, Art

AU - Boers-Sonderen, Marye J

AU - van den Eertwegh, Alfonsus J M

PY - 2021/5/11

Y1 - 2021/5/11

N2 - Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021

AB - Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021

UR - https://www.scopus.com/pages/publications/85102555905

U2 - 10.1038/s41416-021-01312-1

DO - 10.1038/s41416-021-01312-1

M3 - Comment/Letter to the editor

C2 - 33723402

SN - 0007-0920

VL - 124

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 10

M1 - 1746

ER -

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this